Equities analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to announce $218.45 million in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Myriad Genetics’ earnings, with the highest sales estimate coming in at $226.28 million and the lowest estimate coming in at $215.75 million. Myriad Genetics posted sales of $194.00 million during the same quarter last year, which suggests a positive year over year growth rate of 12.6%. The business is expected to announce its next quarterly earnings report on Tuesday, February 5th.
On average, analysts expect that Myriad Genetics will report full year sales of $872.12 million for the current financial year, with estimates ranging from $859.02 million to $891.40 million. For the next fiscal year, analysts expect that the business will post sales of $939.49 million, with estimates ranging from $895.80 million to $1.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Myriad Genetics.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.13. The company had revenue of $202.30 million during the quarter, compared to the consensus estimate of $203.20 million. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. Myriad Genetics’s revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 earnings per share.
Myriad Genetics stock traded up $0.19 during mid-day trading on Monday, hitting $32.24. 1,056,150 shares of the company were exchanged, compared to its average volume of 1,100,902. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.83 and a current ratio of 3.17. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of 26.87, a PEG ratio of 1.86 and a beta of 0.51. Myriad Genetics has a 12-month low of $27.27 and a 12-month high of $50.44.
Several large investors have recently made changes to their positions in MYGN. Quantbot Technologies LP purchased a new stake in shares of Myriad Genetics during the third quarter worth about $130,000. Robecosam AG boosted its position in shares of Myriad Genetics by 39.8% during the second quarter. Robecosam AG now owns 4,193 shares of the company’s stock worth $156,000 after buying an additional 1,193 shares during the period. First Quadrant L P CA acquired a new position in shares of Myriad Genetics during the third quarter worth approximately $201,000. Ibex Investors LLC acquired a new position in shares of Myriad Genetics during the third quarter worth approximately $202,000. Finally, Parametrica Management Ltd acquired a new position in shares of Myriad Genetics during the third quarter worth approximately $204,000. 98.21% of the stock is owned by institutional investors and hedge funds.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Further Reading: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.